Five-year collaboration aims to accelerate clinical development of select novel apoptosis-targeted and tyrosine kinase inhibitor product candidates HOUSTON, ROCKVILLE, MD, and HONG KONG ― The University of Texas MD Anderson Cancer Center and Ascentage Pharma Group, Inc. today announced a five-year strategic collaboration agreement to advance the development of five potential new cancer therapies. The alliance is aimed at developing novel cancer therapeutics based upon Ascentage’s proprietary Protein-Protein Interaction drug discovery technology platform. MD Anderson’s leukemia team will […]
